Bedside monitoring to adjust antiplatelet therapy for coronary stenting.

By J. Collet, T. Cuisset, G. Rangé, G. Cayla, S. Elhadad, C. Pouillot, P. Henry, P. Motreff, D. Carrié, Z. Boueri and 15 more. New England Journal of Medicine, 2012

885 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/edb6f2d2ca101eb61dd2cb5c29b81794805ed531

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. L. Bonello
2. U. Tantry
3. W. Kernan
4. M. Price
5. B. Ovbiagele
6. D. Sibbing
7. Deepak L. Bhatt
8. R. Marcucci

Citations in the corpus

• Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. (2014, background): “In a trial of patients receiving coronary stents, patients assigned to platelet function monitoring and drug adjustment based on these results tended to have more outcome events than patients who were not monitored and did not have their medication adjusted.(555) In another recent report, 250 ischem”
• Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. (2013, methodology): “The evidence from the ARCTIC and GRAVITAS trials have been used to support the hypothesis that HPR is a nonmodifiable risk factor.”